---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-181329"
form_type: "8-K"
ticker: "SLNO"
cik: "0001484565"
company_name: "SOLENO THERAPEUTICS INC"
filed_at: "2024-07-19T23:59:59+00:00"
generated_at: "2026-05-31T19:00:17.677090+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Soleno grants performance-based RSUs to executives tied to DCCR NDA milestones

## Summary
- CEO Anish Bhatnagar receives 850,000 performance-based RSUs; CFO James Mackaness 100,000; SVP Patricia Hirano 85,000.
- Vesting: 25% on Aug 1, 2024; 25% on FDA acceptance of DCCR NDA for Prader-Willi syndrome; 50% on FDA approval.
- Board increased 2014 Equity Incentive Plan by 2,000,000 shares, approved by 68.6% of votes at June 2024 annual meeting.
- Grants aim to bring key employee equity ownership in line with peer group median.

## SEC filing metadata
- accession: 0001193125-24-181329
- form_type: 8-K
- ticker: SLNO
- cik: 0001484565
- company_name: SOLENO THERAPEUTICS INC
- filed_at: 2024-07-19T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1484565/000119312524181329/0001193125-24-181329-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1484565/000119312524181329/d839231d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-181329
- JSON: https://secwatch.observer/filing/0001193125-24-181329.json
- Plain text: https://secwatch.observer/filing/0001193125-24-181329.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.